The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia.
about
Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities.Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cellsDiabetes-associated macrovascular complications: cell-based therapy a new tool?New perspectives in human stem cell therapeutic research.Biomimetic strategies for fracture repair: Engineering the cell microenvironment for directed tissue formation.CD34⁺/M-cadherin⁺ bone marrow progenitor cells promote arteriogenesis in ischemic hindlimbs of ApoE⁻/⁻ mice.Transient inhibition of transforming growth factor-beta1 in human diabetic CD34+ cells enhances vascular reparative functions.Angiotensin-(1-7) reverses angiogenic dysfunction in corpus cavernosum by acting on the microvasculature and bone marrow-derived cells in diabetesN-3 polyunsaturated Fatty acids prevent diabetic retinopathy by inhibition of retinal vascular damage and enhanced endothelial progenitor cell reparative function.Isolation and characterization of mouse bone marrow-derived Lin⁻/VEGF-R2⁺ progenitor cells.Extracellular high mobility group box 1 plays a role in the effect of bone marrow mononuclear cell transplantation for heart failure.Vasoreparative dysfunction of CD34+ cells in diabetic individuals involves hypoxic desensitization and impaired autocrine/paracrine mechanisms.Blockade of NADPH oxidase restores vasoreparative function in diabetic CD34+ cells.Myeloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis through interleukin-8.Circulating angiogenic cell populations, vascular function, and arterial stiffness.Liver X receptor modulates diabetic retinopathy outcome in a mouse model of streptozotocin-induced diabetes.Circulating endothelial and progenitor cells: Evidence from acute and long-term exercise effectsEmbryonic stem cells and inducible pluripotent stem cells: two faces of the same coin?Impaired Mobilization of Vascular Reparative Bone Marrow Cells in Streptozotocin-Induced Diabetes but not in Leptin Receptor-Deficient db/db Mice.The promise of cell-based therapies for diabetic complications: challenges and solutionsGMP-based CD133(+) cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapyEndothelial progenitor cells: quo vadis?Cell-based therapies for diabetic retinopathy.Therapeutic revascularisation of ischaemic tissue: the opportunities and challenges for therapy using vascular stem/progenitor cells.Cord blood endothelial progenitor cells as therapeutic and imaging probes.Endothelial progenitors as tools to study vascular disease.Ex vivo expansion of human outgrowth endothelial cells leads to IL-8-mediated replicative senescence and impaired vasoreparative function.TRPC3-mediated Ca2+ signals as a promising strategy to boost therapeutic angiogenesis in failing hearts: The role of autologous endothelial colony forming cells.Subtypes of endothelial progenitor cells affect healing of segmental bone defects differently.What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction.Reversal of Bone Marrow Mobilopathy and Enhanced Vascular Repair by Angiotensin-(1-7) in Diabetes.Superior Potential of CD34-Positive Cells Compared to Total Mononuclear Cells for Healing of Nonunion Following Bone Fracture.Human blood-derived endothelial progenitor cells augment vasculogenesis and osteogenesis.Expanded CD133+ Cells from Human Umbilical Cord Blood Improved Heart Function in Rats after Severe Myocardial Infarction.
P2860
Q21202035-CC13349B-8147-4C89-98AA-BEE8DE07715BQ30367803-887CB6F8-022A-4A13-B9B1-E9F60B02680AQ30428895-CAF9A94F-4E98-47E4-A95C-E44C29A40D76Q33466529-965DF9E7-1035-40B9-B1E5-AF83F18E1283Q33606524-38688E89-8E7C-49B9-ACEB-4881A9172211Q33934035-F56B681C-DF80-4664-9D35-9FE2C084B4E2Q34024355-71DA231E-D94C-4E84-AC91-E6CB0C1CD3CDQ34111573-941FA100-ADE7-4EFD-BFBB-7ABD2893C65BQ34576158-F132F175-4145-42ED-9C04-604E45C02844Q34774577-7D88A02E-00DA-4961-B1CF-FA96F99F77CFQ35034878-61C8437C-8206-4610-8FFE-1D6E6B93F308Q35142725-7972DBD4-CA3F-421C-AE96-9131C9D3128AQ35221390-9712B6C7-85A5-41AE-8C7C-22C38B9F6B78Q35286823-DFA9342F-F2C7-4231-958E-075C757F0BF4Q35751792-683D3CCD-EB7B-4514-9E7C-8F4A345D82A5Q36410637-246B6F28-08AC-4E8B-B59B-60395300E1A1Q36490364-E218A7F1-213D-47D1-8DD2-17D0D8EBE4BEQ36736355-C74BF378-72D1-42F0-BC4E-BDA0F6DB74F8Q36910839-BCC1E808-2082-4E1F-AEF4-0D7B0CA89205Q37276042-B1DEA68E-F1BB-4A5B-89DE-87041F49B8B7Q37311008-BAFD6CE1-8100-43DF-88E0-AC9089DFF990Q37776785-6D3579CB-2AB0-4FB1-AFD3-EA5DA633FE77Q37879584-40B5E9F5-A0FF-42E7-8C92-5AEE136C87A0Q38035076-26F19694-22D8-4A01-9E9B-89D0A5040186Q38066215-B8A39227-45FB-408E-AAB9-2922A94291BEQ41836574-8CDF4F9E-E617-453E-BD24-903C597D9986Q43495535-A5F59EAF-E702-4480-BCE5-93E81FB7AADEQ47644462-BC3E985F-A46D-4CF6-98C4-835536F3333EQ47755891-9981C2EB-26C0-4DAE-A0E2-8BB3B02602BEQ48062986-29820206-A68B-4B21-B4DC-1117C859A7E0Q51321906-A391045B-C3CC-46C7-A16E-69B94053486AQ51737339-3CE82191-CF8D-4ED1-B9B5-A48FA2D7D369Q53399910-5B8F0CA3-8034-49D5-AB55-1C81750B91ACQ53821193-19E6A3D8-7A32-4F3B-B394-4BABAF5D6A1A
P2860
The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The relative potency and safet ...... rdial infarction and ischemia.
@en
The relative potency and safet ...... rdial infarction and ischemia.
@nl
type
label
The relative potency and safet ...... rdial infarction and ischemia.
@en
The relative potency and safet ...... rdial infarction and ischemia.
@nl
prefLabel
The relative potency and safet ...... rdial infarction and ischemia.
@en
The relative potency and safet ...... rdial infarction and ischemia.
@nl
P2093
P2860
P356
P1476
The relative potency and safet ...... rdial infarction and ischemia.
@en
P2093
Douglas W Losordo
Haruki Sekiguchi
Masaaki Ii
P2860
P304
P356
10.1002/JCP.21672
P577
2009-05-01T00:00:00Z